AR099632A1 - Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos - Google Patents
Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestosInfo
- Publication number
- AR099632A1 AR099632A1 ARP140101475A ARP140101475A AR099632A1 AR 099632 A1 AR099632 A1 AR 099632A1 AR P140101475 A ARP140101475 A AR P140101475A AR P140101475 A ARP140101475 A AR P140101475A AR 099632 A1 AR099632 A1 AR 099632A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- combination
- hepatitis
- compounds
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Abstract
Una combinación que incluye al compuesto (A) y al compuesto (B) o una sal farmacéuticamente aceptable de los mismos, para mejorar y/o tratar una infección viral por hepatitis C. Reivindicación 1: El uso de una cantidad eficaz de una combinación del compuesto (A) y del compuesto (B) o de una sal farmacéuticamente aceptable de los mismos, en la preparación de un medicamento, para mejorar o tratar una infección viral por hepatitis C; en la cual: el compuesto (A) es un compuesto de fórmula (1) y se dosifica en una cantidad variable en el rango de 50 mg a 300 mg y el compuesto (B) es un compuesto de fórmula (2) (daclatasvir) y se dosifica en una cantidad comprendida en el rango que varía entre alrededor de 40 mg y aproximadamente 80 mg. Reivindicación 28: El uso de acuerdo con una cualquiera de las reivindicaciones 1 a 27, en el cual la combinación comprende, asimismo, el compuesto (C) o una sal farmacéuticamente aceptable del mismo, donde el compuesto (C) es un compuesto de fórmula (3) (ribavirina).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361809283P | 2013-04-05 | 2013-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099632A1 true AR099632A1 (es) | 2016-08-10 |
Family
ID=51654869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101475A AR099632A1 (es) | 2013-04-05 | 2014-04-03 | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos |
Country Status (6)
Country | Link |
---|---|
US (1) | US9504705B2 (es) |
AR (1) | AR099632A1 (es) |
AU (1) | AU2014248116A1 (es) |
CA (1) | CA2908313A1 (es) |
TW (1) | TW201532606A (es) |
WO (1) | WO2014165704A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
WO2012088155A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
BR112014014740B1 (pt) | 2011-12-22 | 2021-08-24 | Alios Biopharma, Inc | Compostos de nucleosídeos, nucleotídeos e análogos destes, seu uso e composição farmacêutica |
WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
SG11201407336PA (en) | 2012-05-25 | 2015-03-30 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
EP2935305A4 (en) | 2012-12-21 | 2016-08-03 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF |
CA2894542C (en) | 2012-12-21 | 2023-10-31 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2014165704A1 (en) | 2013-04-05 | 2014-10-09 | Vertex Pharmaceuticals, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
TW201542578A (zh) | 2013-06-26 | 2015-11-16 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
NZ714415A (en) | 2013-06-26 | 2017-09-29 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
TW201524990A (zh) | 2013-10-11 | 2015-07-01 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
AU2015280234B2 (en) | 2014-06-24 | 2021-04-01 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN106573011A (zh) | 2014-06-24 | 2017-04-19 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸和其类似物 |
KR20170073649A (ko) | 2014-10-28 | 2017-06-28 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오시드 유사체의 제조 방법 |
MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
US10208045B2 (en) | 2015-03-11 | 2019-02-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
EA201890818A1 (ru) * | 2015-09-29 | 2018-09-28 | Янссен Фармасьютикалс, Инк. | Режим комбинированной терапии для лечения hcv |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110128947A (ko) | 2009-03-20 | 2011-11-30 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오시드 및 뉴클레오티드 유사체 |
EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
WO2012088155A1 (en) * | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
BR112014014740B1 (pt) * | 2011-12-22 | 2021-08-24 | Alios Biopharma, Inc | Compostos de nucleosídeos, nucleotídeos e análogos destes, seu uso e composição farmacêutica |
WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
WO2013142159A1 (en) * | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN104203253A (zh) | 2012-03-21 | 2014-12-10 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸及其类似物 |
EP2828278A4 (en) * | 2012-03-21 | 2015-12-09 | Alios Biopharma Inc | PROCESSES FOR PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS |
NZ630805A (en) * | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
EP2935305A4 (en) | 2012-12-21 | 2016-08-03 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF |
CA2894542C (en) | 2012-12-21 | 2023-10-31 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US20140309413A1 (en) | 2013-03-11 | 2014-10-16 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
WO2014165704A1 (en) | 2013-04-05 | 2014-10-09 | Vertex Pharmaceuticals, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
NZ714415A (en) | 2013-06-26 | 2017-09-29 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
TW201542578A (zh) | 2013-06-26 | 2015-11-16 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
TW201524990A (zh) | 2013-10-11 | 2015-07-01 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
AU2015280234B2 (en) | 2014-06-24 | 2021-04-01 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
CN106573011A (zh) | 2014-06-24 | 2017-04-19 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸和其类似物 |
NZ727392A (en) | 2014-06-24 | 2018-04-27 | Alios Biopharma Inc | Methods of preparing substituted nucleotide analogs |
EP3171878A4 (en) | 2014-07-22 | 2018-03-14 | Alios Biopharma, Inc. | Methods for treating paramyxoviruses |
SG11201700851WA (en) | 2014-08-05 | 2017-03-30 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
KR20170073649A (ko) | 2014-10-28 | 2017-06-28 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오시드 유사체의 제조 방법 |
MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
-
2014
- 2014-04-03 WO PCT/US2014/032880 patent/WO2014165704A1/en active Application Filing
- 2014-04-03 CA CA2908313A patent/CA2908313A1/en not_active Abandoned
- 2014-04-03 TW TW103112610A patent/TW201532606A/zh unknown
- 2014-04-03 AU AU2014248116A patent/AU2014248116A1/en not_active Abandoned
- 2014-04-03 AR ARP140101475A patent/AR099632A1/es unknown
- 2014-04-03 US US14/244,274 patent/US9504705B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TW201532606A (zh) | 2015-09-01 |
US9504705B2 (en) | 2016-11-29 |
WO2014165704A1 (en) | 2014-10-09 |
US20140303113A1 (en) | 2014-10-09 |
AU2014248116A1 (en) | 2015-11-12 |
CA2908313A1 (en) | 2014-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR099632A1 (es) | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
CL2017000379A1 (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) | |
UY37997A (es) | Agentes antivirales contra la hepatitis b | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CL2015003117A1 (es) | Modificaciones en la estructura cristalina | |
CL2016000381A1 (es) | Compuestos antivirales | |
CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
CL2016000805A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. | |
CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
CR20150337A (es) | Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral | |
CO6761348A2 (es) | Compuestos antivirales | |
CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
AR094553A1 (es) | Formas de oxadiazolpirazina | |
CL2017000329A1 (es) | Mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |